-+ 0.00%
-+ 0.00%
-+ 0.00%

CARDIFF ONCOLOGY - 30 MG ONVANSERTIB PLUS FOLFIRI/BEVACIZUMAB ARM SHOWS ORR OF 72.2% VS 42.1% FOR SOC

Reuters·06/02/2026 13:06:00

Please log in to view news